Free Trial
NASDAQ:UPB

Upstream Bio Q3 2024 Earnings Report

Upstream Bio logo
$8.59 -0.06 (-0.69%)
As of 02:15 PM Eastern

Upstream Bio EPS Results

Actual EPS
-$6.96
Consensus EPS
-$0.58
Beat/Miss
Missed by -$6.38
One Year Ago EPS
N/A

Upstream Bio Revenue Results

Actual Revenue
$0.61 million
Expected Revenue
$0.83 million
Beat/Miss
Missed by -$220.00 thousand
YoY Revenue Growth
N/A

Upstream Bio Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Upstream Bio's Q2 2025 earnings is scheduled for Wednesday, June 11, 2025

Upstream Bio Earnings Headlines

Trump Quietly Planning $15 Trillion Crypto Shocker
Most investors are still unaware, but I believe a new White House action may have quietly opened the floodgates for a $15 trillion crypto surge. My latest crypto playbook reveals the coin I’m most bullish on—including the name, ticker, and why I’m investing personal capital into it.
See More Upstream Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Upstream Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Upstream Bio and other key companies, straight to your email.

About Upstream Bio

Upstream Bio (NASDAQ:UPB), a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

View Upstream Bio Profile

More Earnings Resources from MarketBeat